ClinicalTrials.gg
CompletedNCT00531453Updated Jan 26, 2012Results posted

A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) in Newly Diagnosed Multiple Myeloma

A Phase 2 interventional study of bortezomib, dexamethasone, and thalidomide and bortezomib, dexamethasone, thalidomide, and cyclophosphamide in Multiple Myeloma, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 1 site in Austria. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2012-01-26.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies in Multiple Myeloma by Takeda — 2 open to participants now, 4 under way, 1 of them phase 3. Multiple Myeloma · Takeda.

Enrollment
14th of 38
98 · median 61
Started
2007
with 3 others
Phase 2
7 of 54
none open now
Registered
9th of 54
by date

Among the 54 studies in Multiple Myeloma by Takeda, this one is the 14th largest by enrollment of the 38 interventional ones that give a count, is one of 4 that started in 2007, is one of 7 in phase 2, and was the 9th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

2 of the 54 studies in Multiple Myeloma by Takeda are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Multiple Myeloma by Takeda, or all of them as a file.
02

Study summary

The purpose of this Phase 2 randomized study is to evaluate the efficacy and safety of treatment with a regimen of VELCADE, dexamethasone, and thalidomide (VDT) or VELCADE, dexamethasone, thalidomide, and cyclophosphamide (VDTC) in subjects with newly diagnosed symptomatic multiple myeloma who have received no prior treatment and are candidates to receive high-dose therapy and autologous bone marrow/stem cell transplantation.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female between ≥18 and ≤70 years
  • Patient is a candidate for HDT combined with an SCT
  • Performance Status score of ≥60%
  • Multiple myeloma diagnosed according to the following standard criteria AND requiring systemic therapy:
  • Presence of M-component in serum and/or urine, plus clonal plasma cells in the bone marrow and/or a documented clonal plasmacytoma
  • PLUS 1 or more of the following:

    1. Calcium elevation (>11.5 mg/dL or >2.65 mmol/L)
    2. Renal insufficiency (creatinine >2 mg/dL or >177 umol/L)
    3. Anemia ( \<10 g/dL [\<12.5 mmol/L] or at least 2 mg/dL [1.25 mmol/L] below normal)
    4. Bone disease (lytic lesions or osteopenia)
  • AND fulfill criteria for , as defined by at least 1 of the following 3 measurements:

    1. Serum M-protein ≥1 g/dL (≥10 g/L)
    2. Urine M-protein ≥200 mg/24 h
    3. Serum free light chain (FLC) assay: Involved FLC level ≥10 mg/dL (≥100 mg/L) provided serum FLC ratio is abnormal
  • Women of must agree to use 2 methods of .
  • Males must agree to use barrier contraception.
  • Subjects (or their legally acceptable representatives) must have signed an document.
  • To participate in the optional pharmacogenomic component of this study, subjects (or their legally acceptable representative) must have signed the informed consent form. Refusal to consent for this component does not exclude a subject from participation in the clinical study.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of smoldering OR non-secretory multiple myeloma or monoclonal gammopathy of undetermined significance (MGUS).
  • Diagnosis of Waldenström's disease or other conditions in which IgM M-protein is present in the absence of a clonal plasma cell infiltration with lytic bone lesions.
  • Prior or current systemic therapy for multiple myeloma including .
  • Radiation therapy and/or plasmapheresis within 15 days before randomization.
  • History of allergic reaction attributable to compounds being given (VELCADE, thalidomide, dexamethasone, and/or cyclophosphamide) or compounds containing boron or mannitol.
  • Peripheral neuropathy or neuropathic pain Grade 2 or higher, as defined by National Cancer Institute (NCI CTCAE) Version 3.0.
  • Uncontrolled or severe cardiovascular disease
  • Concurrent medical condition or disease (e.g., active systemic infection, uncontrolled diabetes) that is likely to interfere with study procedures or results, or that in the opinion of the investigator would constitute a hazard for participating in this study.
  • Use of any drugs within 30 days before randomization
  • Pregnant or lactating women: A serum β-hCG pregnancy test must be performed at the Screening visit for female subjects of .
  • Employees of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family members of the employees or the investigator.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
98 participants (actual)

Study arms

  • Experimental
    1

    bortezomib, dexamethasone, and thalidomide

    Drug: bortezomib, dexamethasone, and thalidomide

  • Experimental
    2

    bortezomib, dexamethasone, thalidomide, and cyclophosphamide

    Drug: bortezomib, dexamethasone, thalidomide, and cyclophosphamide

Interventions

  • Drugbortezomib, dexamethasone, and thalidomide

    VELCADE (bortezomib) twice weekly for 4 cycles (4 doses per cycle), prior to high-dose chemotherapy (HDT) and stem cell transplantation(SCT). Subjects will receive VELCADE 1.3 mg/m2 as an intravenous (i.v.) bolus injection on Days 1,4,8, and 11, followed by a 10 day rest period (Days 12 to 21) Dexamethasone 40 mg/day will be given by mouth (p.o.) on Days 1-4 and Days 9-12 in each of 4 cycles. Thalidomide will be given by mouth (p.o.)every day, starting on Day 1 of Cycle 1 (e.g. the same day of the first dose of VELCADE) and continuing until Day 21 of Cycle 4 at a dose of 100 mg/day (bedtime).

  • Drugbortezomib, dexamethasone, thalidomide, and cyclophosphamide

    VELCADE (bortezomib) twice weekly for 4 cycles (4 doses per cycle), prior to high-dose chemotherapy(HDT)and stem cell transplantation(SCT). Subjects will receive VELCADE 1.3 mg/m2 as an intravenous (i.v.) bolus injection on Days 1,4,8, and 11, followed by a 10 day rest period (Days 12 to 21). Dexamethasone 40 mg/day will be given by mouth (p.o.) on Days 1-4 and Days 9-12 in each of 4 cycles. Thalidomide will be given by mouth (p.o.) every day, starting on Day 1 of Cycle 1 (e.g., the same day of the first dose of VELCADE) and continuing until Day 21 of Cycle 4 at a dose of 100 mg/day (bedtime). Cyclophosphamide will be given as an intravenous (i.v.) dose of 400 mg/m2 on Day 1 and Day 8 of each 3-week cycle, for a total of 4 cycles.

06

What researchers measure

Primary outcomes

  1. Percent of Particpants Achieving Overall Combined Complete Response (CR) Following Induction

    Percent of Particpants Achieving Overall combined complete response (CR w/normalized serum κ:λ ratio + CR + near complete response (nCR)) following induction therapy. * CR criteria: negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas and \<5% plasma cells in bone marrow. * κ:λ ratio: normal free light chain (FLC) ratio * nCR criteria: positive immunofixation analysis of serum or urine as the only evidence of disease; disappearance of any soft tissue plasmacytomas and \<5% plasma cells in bone marrow.

    Time frame: all data included in clinical database as of 10 April 2009

Secondary outcomes

  1. Percent of Participants Achieving Overall Combined Complete Response (CR) Following High-dose Chemotherapy (HDT)/Stem Cell Transplantation (SCT)

    Percent of Participants Achieving Overall Combined Complete Response (CR) (CR w/normalized serum κ:λ ratio + CR + Near Complete Response (nCR)) following stem cell transplantation. * CR criteria: negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas and \<5% plasma cells in bone marrow. * κ:λ ratio: normal free light chain (FLC) ratio * nCR criteria: positive immunofixation analysis of serum or urine as the only evidence of disease; disappearance of any soft tissue plasmacytomas and \<5% plasma cells in bone marrow.

    Time frame: all data included in clinical database as of 10 April 2009

07

Results

Posted Jun 4, 2010

Participant flow

98 patients were enrolled between October 2007 and September 2008

Participant flow — Overall Study
MilestoneThree Drug Regimen (VDT)Four Drug Regimen (VDTC)
Started4949
Completed4949
Not completed00

Outcome measures

PrimaryPercent of Particpants Achieving Overall Combined Complete Response (CR) Following Induction

Percent of Particpants Achieving Overall combined complete response (CR w/normalized serum κ:λ ratio + CR + near complete response (nCR)) following induction therapy. * CR criteria: negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas and \<5% plasma cells in bone marrow. * κ:λ ratio: normal free light chain (FLC) ratio * nCR criteria: positive immunofixation analysis of serum or urine as the only evidence of disease; disappearance of any soft tissue plasmacytomas and \<5% plasma cells in bone marrow.

Time frame:
all data included in clinical database as of 10 April 2009
Reported as:
Number · percentage of participants
Percent of Particpants Achieving Overall Combined Complete Response (CR) Following Induction
percentage of participantsThree Drug Regimen (VDT)Four Drug Regimen (VDTC)
Percent of Particpants Achieving Overall Combined Complete Response (CR) Following Induction5144
SecondaryPercent of Participants Achieving Overall Combined Complete Response (CR) Following High-dose Chemotherapy (HDT)/Stem Cell Transplantation (SCT)

Percent of Participants Achieving Overall Combined Complete Response (CR) (CR w/normalized serum κ:λ ratio + CR + Near Complete Response (nCR)) following stem cell transplantation. * CR criteria: negative immunofixation on the serum and urine, disappearance of any soft tissue plasmacytomas and \<5% plasma cells in bone marrow. * κ:λ ratio: normal free light chain (FLC) ratio * nCR criteria: positive immunofixation analysis of serum or urine as the only evidence of disease; disappearance of any soft tissue plasmacytomas and \<5% plasma cells in bone marrow.

Time frame:
all data included in clinical database as of 10 April 2009
Reported as:
Number · percentage of participants
Percent of Participants Achieving Overall Combined Complete Response (CR) Following High-dose Chemotherapy (HDT)/Stem Cell Transplantation (SCT)
percentage of participantsThree Drug Regimen (VDT)Four Drug Regimen (VDTC)
Percent of Participants Achieving Overall Combined Complete Response (CR) Following High-dose Chemotherapy (HDT)/Stem Cell Transplantation (SCT)76 (NE to NE)78 (NE to NE)

Adverse events

Collected over From first dose to 30 days post last dose. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Three Drug Regimen (VDT)—11/49 (22.4%)48/49 (98%)
Four Drug Regimen (VDTC)—20/49 (40.8%)47/49 (95.9%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventThree Drug Regimen (VDT)Four Drug Regimen (VDTC)
Infections and InfestationsInfections and infestations3/497/49
Musculoskeletal and Connective Tissue DisordersMusculoskeletal and connective tissue disorders1/497/49
Gastrointestinal DisordersGastrointestinal disorders4/494/49
General Disorders and administration site ConditionsGeneral disorders4/494/49
Respiratory, Thoracic and mediastinal DisordersRespiratory, thoracic and mediastinal disorders3/494/49
Nervous System DisordersNervous system disorders3/492/49
Blood and Lymphatic System DisordersBlood and lymphatic system disorders1/492/49
Cardiac DisordersCardiac disorders1/492/49
Injury, Poisoning and Procedural ComplicationsInjury, poisoning and procedural complications0/492/49
Metabolism and Nutritional DisordersMetabolism and nutrition disorders1/491/49
Most frequent other events
Showing 10 of 22
Most frequent other events
EventThree Drug Regimen (VDT)Four Drug Regimen (VDTC)
Gastrointestinal DisordersGastrointestinal disorders30/4932/49
Nervous System DisordersNervous system disorders31/4927/49
General Disorders and Administration Site ConditionsGeneral disorders28/4928/49
Blood and Lymphatic System DisordersBlood and lymphatic system disorders15/4922/49
Skin and Subcutaneous Tissue DisordersSkin and subcutaneous tissue disorders18/4912/49
Musculoskeletal and Connective Tissue DisordersMusculoskeletal and connective tissue disorders17/4913/49
Metabolism and Nutrition DisordersMetabolism and nutrition disorders16/4915/49
Infections and InfestationsInfections and infestations15/4911/49
Vascular DisordersVascular disorders8/4913/49
Respiratory, Thoracic and Mediastinal DisordersRespiratory, thoracic and mediastinal disorders9/499/49

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Three Drug Regimen (VDT)Four Drug Regimen (VDTC)Total
<=18 years000
Between 18 and 65 years464490
>=65 years358
Age Continuous
Age Continuous(years)Three Drug Regimen (VDT)Four Drug Regimen (VDTC)Total
Mean55.1 ± 7.0455.8 ± 8.2755.4 ± 7.65
Sex: Female, Male
Sex: Female, Male(Participants)Three Drug Regimen (VDT)Four Drug Regimen (VDTC)Total
Female262551
Male232447
08

Study locations

1 site
  • Wilhelminenspital-1
    Vienna, A-1160, Austria
09

References and documents

Publications

  • Ludwig H; Viterbo L; Greil R; Masszi T; Spicka I; Shpilberg O; Hajek R; Dmoszynska A; Cakana A; Enny C; Feng H; van de Velde H; and Harousseau J-L. Bortezomib, Thalidomide, and Dexamethasone (VTD) Versus VTD Plus Cyclophosphamide as Induction Therapy in Previously Untreated Multiple Myeloma Patients Eligible for HDT-ASCT: A Randomized Phase 2 Trial. Blood (ASH Annual Meeting Abstracts), Nov 2009; 114: 2312.
  • Ludwig H, Greil R, Masszi T, Spicka I, Shpilberg O, Hajek R, Dmoszynska A, Paiva B, Vidriales MB, Esteves G, Stoppa AM, Robinson D Jr, Chaturvedi S, Ataman O, Enny C, Feng H, van de Velde H, Viterbo L. Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up. Br J Haematol. 2015 Nov;171(3):344-54. doi: 10.1111/bjh.13582. Epub 2015 Jul 7. PubMed 26153365 ↗
  • Ludwig H, Viterbo L, Greil R, Masszi T, Spicka I, Shpilberg O, Hajek R, Dmoszynska A, Paiva B, Vidriales MB, Esteves G, Stoppa AM, Robinson D Jr, Ricci D, Cakana A, Enny C, Feng H, van de Velde H, Harousseau JL. Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma. J Clin Oncol. 2013 Jan 10;31(2):247-55. doi: 10.1200/JCO.2011.39.5137. Epub 2012 Oct 22. PubMed 23091109 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2007, a primary completion of Apr 2009 and a completion of May 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2010, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2007
First posted
Sep 18, 2007
Start
Oct 2007
Primary completionActual
Apr 2009
CompletionActual
May 2009
Results first posted
Jun 4, 2010
Last update
Jan 26, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00531453
Responsible party
Sponsor
First posted
Sep 18, 2007
Start date
Oct 2007
Primary completion
Apr 2009
Completion
May 2009
Results posted
Jun 4, 2010
Last update
Jan 26, 2012

Study contacts

Medical Monitor
study director · Millennium Pharmaceuticals, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion